IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(10):2137-2144

Original Article
Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma

Xiao-Yu Li , Qi-Feng Luo, Jia Li, Chuan-Kui Wei, Xiang-Jie Kong, Jun-Feng Zhang, Lin Fang

Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China

Received July 24, 2013; Accepted August 28, 2013; Epub September 15, 2013; Published October 1, 2013

Abstract: Background: NIN/RPN Binding protein 1 homologue (NOBp1), encoded by NOB1 gene, was reported to play an essential role in the
oncogenesis and prognosis of carcinomas. We conducted a study to reveal its expression and clinical significance in breast infiltrating ductal
carcinoma. Methods: To explore the relationship between NOB1 expression and the clinical TNM (cTNM), 162 patients who undergone surgery
were involved in the study. Compared to healthy tissues, abnormal localization and higher level of NOB1 in tumor cells was observed by
Immunohistochemistry staining. Real-time PCR and western-blotting verified the up-regulation of NOB1 in carcinoma individuals. Results: A
significant correlation between high level of NOB1 and the T stage, lymph node metastasis and cTNM was shown. Furthermore, patients with
higher level of NOB1 predicted a declined overall survival (OS). Notably, multivariate analyses by Cox’s proportional hazard model revealed that
expression of NOB1 was an independent prognostic factor in breast infiltrating ductal carcinoma. Conclusions: In summary, our present study
clarify that the aberrant expression of NOB1 in breast infiltrating ductal carcinoma is possibly involved with tumorigenesis and development,
and the NOB1 protein could act as a potential biomarker for prognosis assessment of breast infiltrating ductal carcinoma. Related mechanism
is worthy of further investigation. (IJCEP1307042).

Keywords: Breast cancer, NOB1 protein, immunohistochemistry, tissue microarray

Address correspondence to: Dr. Lin Fang or Xiao-Yu Li, Department of Breast and Thyroid Surgery, Shanghai Tenth People’s Hospital, Tongji
University, Shanghai, 200072, China. E-mail: fanglin_f@126.com (LF); 1132502lxy@tongji.edu.cn (XYL)